Polymorphs of the hydrobromide salt of linaprazan glurate
AssigneeCinclus Pharma Holding AB (Publ)
InventorsMikael Hillgren, Lars-Erik Briggner, Emelie Haettner
Life of this patent
Estimating the term…
Abstract
The present invention relates to polymorphs of the hydrobromide salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazanglurate), more specifically Form A, Form B and Form C of the HBr salt of linaprazan glurate. The invention also relates to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases, in particular erosive gastroesophageal reflux disease (eGERD).
Claims26
A crystalline HBr salt of linaprazan glurate.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.